胸部放疗和奥希替尼同步治疗的患者中观察到放射性肺炎发生率特别高。
An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.
机构信息
Department of Radiation Oncology, Shandong Cancer Hospital and Institute Affiliated to Shandong University, Jinan, China.
Department of Thoracic Surgery, Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
出版信息
Radiother Oncol. 2020 Nov;152:96-100. doi: 10.1016/j.radonc.2020.07.051. Epub 2020 Jul 31.
PMID:32745669
Abstract
Our study is the first to report an especially high rate of grade 2 or worse radiation pneumonitis in patients treated with thoracic radiotherapy and simultaneous Osimertinib, despite total lung V5, V20 and MLD seeming unlikely to induce radiation pneumonitis.
摘要
我们的研究首次报告了在接受胸部放疗和同时使用奥希替尼治疗的患者中，2 级或更严重放射性肺炎的发生率特别高，尽管全肺 V5、V20 和 MLD 似乎不太可能导致放射性肺炎。
Zotero 插件